SG11201501751RA - Anti-fibrotic pyridinones - Google Patents

Anti-fibrotic pyridinones

Info

Publication number
SG11201501751RA
SG11201501751RA SG11201501751RA SG11201501751RA SG11201501751RA SG 11201501751R A SG11201501751R A SG 11201501751RA SG 11201501751R A SG11201501751R A SG 11201501751RA SG 11201501751R A SG11201501751R A SG 11201501751RA SG 11201501751R A SG11201501751R A SG 11201501751RA
Authority
SG
Singapore
Prior art keywords
pyridinones
fibrotic
fibrotic pyridinones
Prior art date
Application number
SG11201501751RA
Inventor
Brad Owen Buckman
John Beamond Nicholas
Johnnie Y Ramphal
Kumaraswamy Emayan
Scott D Seiwert
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501751R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of SG11201501751RA publication Critical patent/SG11201501751RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
SG11201501751RA 2012-10-02 2013-10-01 Anti-fibrotic pyridinones SG11201501751RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261709075P 2012-10-02 2012-10-02
US201361777499P 2013-03-12 2013-03-12
US201361872157P 2013-08-30 2013-08-30
PCT/US2013/062910 WO2014055548A1 (en) 2012-10-02 2013-10-01 Anti-fibrotic pyridinones

Publications (1)

Publication Number Publication Date
SG11201501751RA true SG11201501751RA (en) 2015-04-29

Family

ID=50435378

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501751RA SG11201501751RA (en) 2012-10-02 2013-10-01 Anti-fibrotic pyridinones

Country Status (36)

Country Link
US (5) US20150266899A1 (en)
EP (1) EP2903991B1 (en)
JP (2) JP6326053B2 (en)
KR (2) KR102176667B1 (en)
CN (2) CN108503575A (en)
AR (1) AR092742A1 (en)
AU (2) AU2013327505B2 (en)
BR (1) BR112015006341B1 (en)
CA (2) CA2884251C (en)
CL (1) CL2015000816A1 (en)
CO (1) CO7350637A2 (en)
CR (1) CR20150225A (en)
DK (1) DK2903991T3 (en)
EA (2) EA027120B1 (en)
EC (1) ECSP15017109A (en)
ES (1) ES2835331T3 (en)
HK (1) HK1212981A1 (en)
HR (1) HRP20201934T1 (en)
HU (1) HUE051581T2 (en)
IL (3) IL237629B (en)
LT (1) LT2903991T (en)
MX (2) MX2020010037A (en)
MY (1) MY174897A (en)
NZ (2) NZ707083A (en)
PE (2) PE20151415A1 (en)
PH (1) PH12015500735A1 (en)
PL (1) PL2903991T3 (en)
PT (1) PT2903991T (en)
RS (1) RS61225B1 (en)
SA (1) SA515360217B1 (en)
SG (1) SG11201501751RA (en)
SI (1) SI2903991T1 (en)
TW (2) TWI644898B (en)
UA (1) UA120908C2 (en)
WO (1) WO2014055548A1 (en)
ZA (1) ZA201502457B (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne.
SG11201407534PA (en) 2012-06-13 2014-12-30 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00960A (en) 2012-09-25 2015-06-12 Hoffmann La Roche
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
US9315464B1 (en) 2013-01-31 2016-04-19 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
WO2015106150A1 (en) 2014-01-10 2015-07-16 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6554481B2 (en) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Fused [1,4] diazepine compounds as inhibitors of autotaxin (ATX) and lysophosphatidic acid (LPA) production
HUE046820T2 (en) 2014-03-26 2020-03-30 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US9394305B2 (en) * 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
MA40943A (en) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
JP6639497B2 (en) 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド Bromodomain inhibitors and uses thereof
MA40940A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
ES2904258T3 (en) 2015-08-12 2022-04-04 Neomed Inst Substituted benzimidazoles, their preparation and their use as pharmaceuticals
CN105085383B (en) * 2015-08-19 2017-09-01 四川大学 5 methyl 2 (1H) Pyridione derivatives and its production and use
CR20180058A (en) 2015-09-04 2018-02-26 Hoffmann La Roche NEW DERIVATIVES OF PHENOXIMETILO
MX2018001890A (en) 2015-09-24 2018-06-20 Hoffmann La Roche Bicyclic compounds as atx inhibitors.
CN107922415B (en) 2015-09-24 2022-04-15 豪夫迈·罗氏有限公司 Novel bicyclic compounds as dual ATX/CA inhibitors
MX2017015034A (en) 2015-09-24 2018-04-13 Hoffmann La Roche New bicyclic compounds as dual atx/ca inhibitors.
KR20180054830A (en) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 Bifunctional compounds as autotaxine (ATX) inhibitors
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
CN108349956A (en) * 2015-10-22 2018-07-31 赛尔维他股份公司 Pyridione derivatives and its purposes as kinase inhibitor
US20180319813A1 (en) * 2015-11-04 2018-11-08 Idemitsu Kosan Co., Ltd Benzimidazole fused heteroaryls
CN105330598B (en) * 2015-12-02 2017-11-14 新发药业有限公司 A kind of preparation method of pirfenidone
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN105541715B (en) * 2016-02-02 2019-04-09 浙江工业大学 (2H) the -one derivative of polysubstituted pyridine -1 and its synthetic method and application
CN105732497B (en) * 2016-02-02 2019-02-01 浙江工业大学 2- aryl -4- methyl ring and (2H) the -one analog derivative of pyridine -1 and its synthetic method and application
US10604513B2 (en) 2016-04-14 2020-03-31 Shijiazhuang Sagacity New Drug Development Co., Ltd. Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN116082225A (en) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 Preparation method of hydroxynisone
CN107698498A (en) * 2016-08-08 2018-02-16 罗楹 A kind of preparation method of oxycodone
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
EP3548025A1 (en) 2016-11-30 2019-10-09 Genentech, Inc. Methods of administering anti-fibrotic therapy
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CR20190423A (en) 2017-03-16 2019-11-01 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
TWI788343B (en) * 2017-04-18 2023-01-01 美商塞爾基因定量細胞研究公司 Therapeutic compounds
US20200165203A1 (en) * 2017-07-31 2020-05-28 Washington University Use of pirfenidone and derivatives for modulation of b lymphocyte activity and organ protection from acute tissue damage
MX366086B (en) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage.
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3459939A1 (en) * 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
CN111278820B (en) * 2017-10-13 2022-11-08 广州嘉越医药科技有限公司 Crystal form and salt form of pyridone compound and preparation method thereof
SI3746441T1 (en) * 2018-02-02 2023-08-31 Genentech Inc. Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
US11171132B2 (en) * 2019-10-03 2021-11-09 Globalfoundries U.S. Inc. Bi-directional breakdown silicon controlled rectifiers
EP4069227A1 (en) 2019-12-04 2022-10-12 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
JP2023535096A (en) * 2020-07-23 2023-08-15 シトシンラボ セラピューティクス カンパニー， リミテッド Compounds having kinase inhibitory activity
CN114129517A (en) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 AK3287 preparation, and preparation method and application thereof
CN116888116A (en) * 2021-02-02 2023-10-13 里米诺生物科学有限公司 GPR84 antagonists and uses thereof
TWI820720B (en) * 2021-05-20 2023-11-01 大陸商廣州嘉越醫藥科技有限公司 Application of a pyridone derivative containing a heteroatom cyclobutane substituent
CN113234013B (en) * 2021-05-21 2022-05-24 杭州医学院 Compound for inhibiting collagen synthesis and deposition and application thereof
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
CN116332947A (en) * 2021-12-24 2023-06-27 上海海和药物研究开发股份有限公司 Pyrimidine-2 (1H) -keto bicyclic compounds with MAT2A inhibitory activity and application thereof
CN116514803A (en) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 Salt crystal form and free alkali crystal form of kinase inhibitor

Family Cites Families (558)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1070639B (en) 1959-12-10 Farbenfabriken Bayer Aktiengesellschaft, Levenkusen-Bayerwerk Process for the preparation of Peptiderj
DE149666C (en)
CH312531A (en) 1952-06-20 1955-12-31 Ciba Geigy Process for making a pyridazone.
CH312530A (en) 1952-06-20 1955-12-31 Ciba Geigy Process for making a pyridazone.
GB788393A (en) 1953-04-30 1958-01-02 Ciba Ltd Process for the manufacture of pyridazone compounds
CH333366A (en) 1953-09-04 1958-10-15 Ciba Geigy Process for the production of new pyridazones
DE1070639C2 (en) 1958-09-30 1964-04-16
US3014034A (en) 1959-01-22 1961-12-19 Ciba Pharm Prod Inc 1, 3-diaryl, 5-amino-pyridazinones
GB889317A (en) 1959-01-22 1962-02-14 Ciba Ltd New phenyl-diazines and a process for their manufacture
JPS422264Y1 (en) 1966-08-10 1967-02-10
US3622340A (en) 1968-08-12 1971-11-23 Eastman Kodak Co 4-thiouracil compounds as fog inhibitors
US3644375A (en) * 1968-10-18 1972-02-22 Toray Industries Lactam dicarboxylic acids and process for producing them
GB1237031A (en) * 1969-03-07 1971-06-30 Toray Industries Lactam dicarboxylic acids and a process for their production
UST866035I4 (en) 1969-05-05 1969-09-30 Defensive publication
FR2081572B1 (en) * 1970-03-12 1973-04-06 Rhone Poulenc Sa
BE787523A (en) 1971-08-13 1973-02-12 Chem Pharmac Fabrik Dr Hermann PYRIDONE-2 MEDICINAL PRODUCT
DE2143744A1 (en) 1971-09-01 1973-03-08 Hoechst Ag 3,4-DIHYDRO-2H-ISOCHINOLIN-1-ONE AND THE METHOD FOR MANUFACTURING IT
DE2366349C2 (en) 1972-12-18 1986-03-27 Affiliated Medical Research Inc., Princeton, N.J. Process for the preparation of 5-methyl-1-phenyl-2- (1H) -pyridone
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
AT333774B (en) 1974-09-24 1976-12-10 Chemie Linz Ag PROCESS FOR THE PREPARATION OF 3-PHENYLPYRIDAZONES
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
DE2557342A1 (en) 1975-12-19 1977-06-30 Hoechst Ag BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
US4258052A (en) 1976-08-17 1981-03-24 Yu Ruey J Treatment of psoriasis with nicotinamide analogues
DE2707268A1 (en) 1977-02-19 1978-08-31 Hoechst Ag Indole-3-carboxaldehyde oxime derivs. - with hypouricaemic, analgesic, antiinflammatory, hypoglycaemic, cardiovascular and diuretic activity
GB1596887A (en) 1977-07-15 1981-09-03 Rohm & Haas 2-pyridone derivatives and their use as plant growth regulators
JPS557201A (en) 1978-05-23 1980-01-19 Shionogi & Co Ltd Derivative of tetrahydrothiopyrano(2,3-b)indole
GB2044272B (en) 1979-02-05 1983-03-16 Sandoz Ltd Stabilising polymers
DD149666A1 (en) 1979-06-27 1981-07-22 Karl Gewald PROCESS FOR THE PREPARATION OF 6-AMINO AND 6-HYDROXY-1-ARYL-5-CYAN-2 (1H) -PYRIDINONE AND THIONES
JPS5721388A (en) 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
JPS5777671A (en) 1980-10-31 1982-05-15 Yasumitsu Tamura Preparation of hydroxyindoles ( or 1,4-dihydroisoquinolones) and their intermediate
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4473696A (en) 1982-10-07 1984-09-25 Ici Americas Inc. Synthesis of 2-substituted-5-methyl-pyridines
US4645839A (en) 1982-12-17 1987-02-24 Ici Americas Inc. Sulphur dehydrogenation process to yield 5-methyl-2-pyridone
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
US4576942A (en) 1984-07-12 1986-03-18 Usv Pharmaceutical Corp. Anti-allergic and anti-inflammatory bi- and tri- cyclo-1,4-thiazine derivatives, composition, and method of use therefor
DK175432B1 (en) * 1984-10-30 2004-10-18 Otsuka Pharma Co Ltd Agent for enhancing the anticancer effect of anticancer compounds
EP0180897B1 (en) * 1984-10-30 1991-08-07 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
JPS6256187A (en) 1985-09-05 1987-03-11 Ricoh Co Ltd Thermal recording material
US4760083A (en) 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
US5173489A (en) 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
DE3805746C2 (en) 1987-03-05 2003-04-10 Clariant Finance Bvi Ltd 1: 2 chromium complex dyes
JPS63290821A (en) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd Antiarrhythmic
DK641487A (en) 1987-12-07 1989-06-08 Gluetech Aps PROCEDURE FOR MODIFYING POLYMER SURFACES
DE3807295A1 (en) 1988-03-05 1989-09-14 Basf Ag NEW N-HETEROARYL TETRAHYDROPHTHALIMIDE COMPOUNDS
JP2614081B2 (en) 1988-05-27 1997-05-28 大塚化学株式会社 Method for producing optically active β-lactam derivative
JPH022264A (en) 1988-06-14 1990-01-08 Canon Inc Message communication system
US5167941A (en) 1988-11-29 1992-12-01 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors in amine scrubbing of SO2
US5019365A (en) 1988-11-29 1991-05-28 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors
GB8901836D0 (en) 1989-01-27 1989-03-15 Sobio Lab Compounds
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5077142A (en) 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
JPH0343744A (en) 1989-07-12 1991-02-25 Hitachi Chem Co Ltd Electrophotographic sensitive body
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
IE910980A1 (en) 1990-03-27 1991-10-09 Smithkline Beecham Corp 5-lipoxygenase inhibitors
JPH0444235A (en) 1990-06-08 1992-02-14 New Japan Radio Co Ltd Manufacture of high-speed bipolar transistor
JPH0449567A (en) 1990-06-19 1992-02-18 Matsushita Electric Ind Co Ltd Magnetic recording and reproducing device
EP0478195B1 (en) 1990-09-21 1999-05-26 Rohm And Haas Company Dihydropyridazinones and pyridazinones as fungicides
JPH04223457A (en) 1990-12-26 1992-08-13 Konica Corp Silver halide photographic sensitive material
AU1191292A (en) 1991-02-11 1992-09-07 Schering Agrochemicals Limited Imidazole pesticides
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
KR100245252B1 (en) 1991-05-15 2000-03-02 도로시 케이. 로빈슨 Determination of prodrugs metabolizable by the liver and therapeutic use thereof
JPH0519023A (en) 1991-07-11 1993-01-26 Hitachi Ltd Integrated circuit device
DE69115692T2 (en) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermally transferable fluorescent compounds
DE69224507T2 (en) 1991-12-26 1998-08-20 Mitsubishi Chem Corp Beta-oxo-beta-benzene propanthioamide derivatives
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
EP0636132A1 (en) 1992-04-16 1995-02-01 The Du Pont Merck Pharmaceutical Company Substituted nitrogen containing spiro compounds for use in treating cognitive deficits
AU4376893A (en) 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
DE4237656A1 (en) 1992-06-13 1993-12-16 Merck Patent Gmbh benzimidazole derivatives
US5459269A (en) * 1992-06-18 1995-10-17 North Carolina State University 14-halo-camptothecins
CA2099743A1 (en) 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5356904A (en) 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4242451A1 (en) 1992-12-16 1994-06-23 Basf Ag Process for the preparation of 5-ring heterocycles
WO1994017059A1 (en) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Heterocyclic derivative
JPH06256187A (en) 1993-03-02 1994-09-13 Fujisawa Pharmaceut Co Ltd Antitussive expectorant containing qunolizinone compound or its salt
DE69431433T2 (en) 1993-05-07 2003-12-04 Solomon B Margolin COMPOSITIONS AND METHODS FOR REPAIRING AND PREVENTING FIBROTIC INJURIES
JP3507124B2 (en) 1993-05-26 2004-03-15 塩野義製薬株式会社 Method for producing benzylidene derivative
DE4423934A1 (en) 1993-09-02 1995-03-09 Basf Ag 3(2H)-Pyridazinone derivatives, their preparation and their use
TW403741B (en) 1993-10-15 2000-09-01 Takeda Chemical Industries Ltd Triazine derivative, production and use thereof
JPH07128793A (en) 1993-11-05 1995-05-19 Konica Corp Fine solid particle dispersion of dye and silver halide photographic sensitive material containing the same
EP0677519A4 (en) 1993-11-10 1996-04-03 Japan Tobacco Inc Chroman derivative and medicinal use thereof.
WO1995016712A1 (en) 1993-12-15 1995-06-22 Smithkline Beecham Corporation Compounds and methods
JPH07233072A (en) 1993-12-28 1995-09-05 Tanabe Seiyaku Co Ltd Medicine composition
JP3572617B2 (en) 1993-12-29 2004-10-06 藤沢薬品工業株式会社 Pyrazolopyridine adenosine antagonist
JP3781200B2 (en) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 Processing method of silver halide photographic light-sensitive material
JP3261641B2 (en) 1994-04-28 2002-03-04 コニカ株式会社 Processing method of silver halide photographic material
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
JP2794392B2 (en) 1994-07-22 1998-09-03 大同テック株式会社 High pressure gas container maintenance equipment
JPH08134371A (en) 1994-11-02 1996-05-28 Konica Corp Dispersion of solid fine particle, silver halide photosensitive material and image forming method
EP0717143A1 (en) 1994-12-16 1996-06-19 Lignozym GmbH Multicomponents system for modifying decomposing or bleaching of lignin or materials containing it or similar components and the way to use it
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
JPH11501911A (en) 1995-03-03 1999-02-16 ビー マーゴリン、ソロモン Treatment of diseases caused by cytokine growth factors
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US5869428A (en) 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
WO1996033994A1 (en) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
DE19520613A1 (en) 1995-06-06 1996-12-12 Bayer Ag Phenylpyridazinones
JPH0933072A (en) 1995-07-18 1997-02-07 Hitachi Ltd Heat storage water tank and multi ice-heat-storage unit
US5945417A (en) 1995-07-31 1999-08-31 Novo Nordisk Heterocyclic compounds, their preparation and use
EP0843660A1 (en) 1995-07-31 1998-05-27 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
AR003978A1 (en) 1995-08-25 1998-09-30 Rohm & Haas COMPOSITIONS OF FATTY ACIDS AND PYRIDAZINONES THAT HAVE SYNERGIC FUNGITOXIC EFFECTS AND METHODS FOR CONTROLLING FUNGI.
WO1997010712A1 (en) 1995-09-19 1997-03-27 Margolin Solomon B Inhibition of tumor necrosis factor alpha
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
DE19535501A1 (en) 1995-09-25 1997-03-27 Bayer Ag Pyridonmethidazo dyes
JPH0995165A (en) 1995-09-29 1997-04-08 Tachi S Co Ltd Longitudinal tilt mechanism for seat
JPH0995166A (en) 1995-10-02 1997-04-08 Tatsuya Mikami Seat for vehicle
JPH09249567A (en) 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd Medicinal composition
JPH09204932A (en) 1996-01-25 1997-08-05 Fujitsu Ltd Electrolyte for lithium secondary battery, and lithium secondary battery
IT1286545B1 (en) 1996-02-09 1998-07-15 Antonio Guarna BENZO (C) QUINOLYZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASE INHIBITORS
JPH09244235A (en) 1996-03-14 1997-09-19 Toshiba Corp Alkali-developable resist
EP0889878B1 (en) 1996-03-29 2002-09-04 Merck Frosst Canada & Co. Bisarylcyclobutene derivates as cyclooxygenase inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
JPH09319023A (en) 1996-05-27 1997-12-12 Fuji Photo Film Co Ltd Thermosensitive recording material
JP3418624B2 (en) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド Substituted imidazoles having cytokine inhibitory activity
AR009811A1 (en) 1996-09-26 2000-05-03 Novartis Ag HERBICIDE COMPOUNDS, PROCESS FOR ITS PRODUCTION, PROCESS FOR THE PRODUCTION OF INTERMEDIARIES, INTERMEDIARY COMPOUNDS FOR ITS EXCLUSIVE USE IN SUCH PROCESS, COMPOSITION THAT HAS A SELECTIVE HERBICIDE ACTIVITY AND A PROCESS FOR THE SELECTIVE CONTROL OF GRASSES AND GRASSES
CA2216512A1 (en) 1996-10-11 1998-04-11 Rohm And Haas Company Dihydropyridazinones and pyridazinones their use as fungicides and insecticides
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19754348A1 (en) 1996-12-11 1998-06-18 Ciba Geigy Ag New 2-(hetero)aryl-2(3H)-pyridazinone derivatives
WO1998029119A1 (en) 1996-12-30 1998-07-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
DE19708928A1 (en) 1997-03-05 1998-09-10 Bayer Ag Substituted aromatic amino compounds
EP0983334A1 (en) 1997-05-12 2000-03-08 Call, Krimhild Enzymatic bleaching system containing new compounds for intensifying enzymatic action
DE19821263A1 (en) 1997-05-12 1998-11-19 Call Krimhild Enzymatic bleach system containing mediator to enhance performance in bleaching textile fabric
JP3043744U (en) 1997-05-26 1997-11-28 株式会社新和 bag
DE19726241A1 (en) 1997-06-20 1998-12-24 Call Krimhild Enhanced multi-component enzymatic system for the treatment of waste water, for the production of wood composites, for deinking waste paper, color stripping of waste paper, for use as an oxidation system in organic synthesis and for use in coal liquefaction
DE19729061A1 (en) 1997-07-08 1999-01-14 Agfa Gevaert Ag Colour photographic material sensitised without increased fogging
SE9702651D0 (en) 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
SE9702794D0 (en) 1997-07-24 1997-07-24 Astra Pharma Prod New compounds
DE19731784A1 (en) 1997-07-24 1999-02-04 Bayer Ag Substituted N-aryl-N-thioxocarbonyl sulfonamides
JPH1149755A (en) 1997-07-30 1999-02-23 Nippon Kayaku Co Ltd New nitrogen containing heterocyclic derivative and acaricide composition using the same as active component
ITFI970193A1 (en) 1997-08-01 1999-02-01 Applied Research Systems USE OF BENZO (C) QUINOLYZINE DERIVATIVES AS REGULATORS OF PLANT GROWTH AND COMPOSITIONS FOR AGRICULTURAL USE CONTAINING SUCH
ES2260846T3 (en) 1997-08-22 2006-11-01 Abbott Laboratories INHIBITORS FOR THE BIOSYNTHESIS OF PROSTAGLANDINA H2 SINTASA.
WO1999010331A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
AU9309898A (en) 1997-09-09 1999-03-29 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
HUP0004151A3 (en) 1997-10-27 2001-12-28 Isk Americas Inc Concord Herbicidal substituted benzene derivatives, intermediates, preparation and use thereof
JP2001524480A (en) 1997-11-21 2001-12-04 アストラゼネカ ユーケイ リミテッド Novel compounds that are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
JPH11180952A (en) 1997-12-19 1999-07-06 Maruho Co Ltd 2-oxindole derivative
ATE389636T1 (en) 1997-12-19 2008-04-15 Amgen Inc SUBSTITUTED PYRIDINE AND PYRIDAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
AU2108099A (en) * 1998-01-30 1999-08-16 Procept, Inc. Immunosuppressive agents
DE19803667A1 (en) 1998-01-30 1999-08-05 Max Planck Gesellschaft Process for the preparation of 5-alkoxy (or 5-aroxy) -2,3-dihydrofuran-2-ones
FR2774986A1 (en) 1998-02-16 1999-08-20 Rhodia Chimie Sa Masked isocyanates made by reacting an isocyanate starting material with a masking agent having a pyronoid structure and a reactive hydrogen atom
CA2322994A1 (en) 1998-03-17 1999-09-23 Solomon B. Margolin Topical antiseptic compositions and methods
CA2312953A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
AU742108B2 (en) 1998-04-09 2001-12-20 Bayer Aktiengesellschaft Substituted phenyl pyridazinones
AP2000001991A0 (en) 1998-04-27 2000-12-31 Centre Nat Rech Scient 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
DE69934224T2 (en) 1998-04-27 2007-10-04 Kumiai Chemical Industry Co., Ltd. 3-ARYLPHENYLSULFIDE DERIVATIVES AND INSECTICIDES AND MITICIDES
ES2273487T3 (en) 1998-06-01 2007-05-01 Astellas Pharma Inc. ADENOSINE A1 ANTAGONISTS AGAINST MALE STERILITY.
FR2779429B1 (en) 1998-06-03 2000-07-13 Synthelabo OXINDOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS
DE19826671A1 (en) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-oxazoline and 1,3-thiazoline derivatives, processes for their preparation and their use as pesticides
DE69810518D1 (en) 1998-09-18 2003-02-06 Mepha Ag Aesch TOPICALLY ADMINISTRABLE ALKYL, PHENYL PYRIDONE MEDICINAL PRODUCTS
WO2000025789A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis
JP3043744B1 (en) 1999-03-17 2000-05-22 日本ピラー工業株式会社 Method for growing single crystal SiC
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
DE19918725A1 (en) 1999-04-24 2000-10-26 Bayer Ag New heterocyclic-substituted N-cyano-sulfonanilide compounds, useful as total or selective pre- or post-emergence herbicides, showing desiccant, defoliant, germination inhibiting and especially weed-killing activities
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
KR100767199B1 (en) 1999-05-07 2007-10-17 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
FR2797629B1 (en) 1999-08-19 2001-09-21 Rhodia Chimie Sa USE OF PYRONE (S) OR THE LIKE TO MASK ISOCYANATES, MASKING PROCESS, ISOCYANATES THUS MASKED, COMPOSITION CONTAINING SAME, COATING METHOD USING SAME, COATING THUS OBTAINED
AT408223B (en) 1999-12-27 2001-09-25 Dsm Fine Chem Austria Gmbh METHOD FOR THE PRODUCTION OF OXINDOLS
AU779442B2 (en) 2000-01-20 2005-01-27 Eisai Co. Ltd. Novel piperidine compounds and drugs containing the same
AU2001234690A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (en) 2000-02-04 2006-03-27 Portola Pharm Inc The platelet ADP receptor inhibitor
GB0002740D0 (en) 2000-02-07 2000-03-29 Novartis Ag Organic compounds
WO2001058448A1 (en) 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Apoptosis inhibitor
MXPA02008132A (en) 2000-02-21 2004-11-12 Solomon B Margolin Compositions and methods for treatment of epilepsy.
ATE347557T1 (en) 2000-03-23 2006-12-15 Takeda Pharmaceutical FLUORISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
DE10024938A1 (en) 2000-05-19 2001-11-22 Bayer Ag New substituted iminoazine derivatives useful as herbicides, especially for weed control in crops
AU2001258825A1 (en) 2000-05-29 2001-12-11 Shionogi And Co., Ltd. Method for labeling with tritium
US6949571B2 (en) 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
DE10034803A1 (en) 2000-07-18 2002-01-31 Bayer Ag Substituted sulfonic acid anilides
CN1446202A (en) 2000-08-11 2003-10-01 卫材株式会社 2-aminopyridine compounds and use thereof as drugs
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
HU228961B1 (en) 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
JP2004509867A (en) 2000-09-19 2004-04-02 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） Pyridinone and pyridinethione derivatives having HIV inhibitory properties
CN1120151C (en) 2000-10-24 2003-09-03 大连化学工业股份有限公司 Prepn of lactam
AU2001297622A1 (en) 2000-10-27 2002-09-12 Dow Agrosciences Llc Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones, and their use as fungicides and insecticides
CA2436854A1 (en) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
YU52403A (en) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
US7160912B2 (en) 2000-12-26 2007-01-09 Dr.Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
ATE438624T1 (en) 2000-12-28 2009-08-15 Shionogi & Co 2-PYRIDONE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID TYPE 2 RECEPTOR
EP1356816B1 (en) 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2002062816A1 (en) * 2001-02-07 2002-08-15 Celltech R & D Limited Non-natural nucleotides and dinucleotides
DE10108995A1 (en) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituted pyrimidinone derivatives as ligands of integrin receptors
JPWO2002085858A1 (en) 2001-04-20 2004-08-12 旭硝子株式会社 Method for producing purified piperidine derivative
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
AU2002316180A1 (en) 2001-06-01 2002-12-16 The Regents Of The University Of California Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
JP2002371078A (en) 2001-06-12 2002-12-26 Sankyo Co Ltd Quinoline derivative and quinolone derivative
JP4180254B2 (en) 2001-06-29 2008-11-12 独立行政法人科学技術振興機構 Method for producing nitrogen-containing 6-membered ring
JP2003021901A (en) 2001-07-05 2003-01-24 Fuji Photo Film Co Ltd Method for photopolymerizing photosensitive lithographic printing plate
KR100898888B1 (en) 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 Process for preparation of 5-methyl-1-phenyl-21h-pyridinone
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (en) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CN1257901C (en) 2001-11-08 2006-05-31 中国科学院上海药物研究所 Tetrahydroquinoline ketopiperidine compounds and their prepn and use
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB0129391D0 (en) 2001-12-07 2002-01-30 Syngenta Participations Ag Microbiocidal n-phenyl-n-[4-(4-pyridyl)-2-pyrimidin-2-yl]-amine derivatives
JP2005170790A (en) 2002-01-09 2005-06-30 Ajinomoto Co Inc N-alkylsulfonyl-substituted amide derivative
WO2003059891A1 (en) 2002-01-18 2003-07-24 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
JP2003238611A (en) 2002-02-18 2003-08-27 Japan Polyolefins Co Ltd Catalyst component for polymerizing olefins, catalyst for polymerizing olefins and method for producing olefins
EP2130820A1 (en) 2002-02-19 2009-12-09 Shionogi & Co., Ltd. Antipruritics
JP2003261535A (en) 2002-03-08 2003-09-19 Mitsubishi Chemicals Corp Method for producing 2-hydroxy-5-methylpyridine
US20060046999A1 (en) 2002-03-14 2006-03-02 Cristina Alonso-Alija Monocyclic aroylpyridinones as antiinflammatory agents
WO2003082265A2 (en) 2002-04-02 2003-10-09 Fujisawa Pharmaceutical Co Pharmaceutical composition for treating or preventing virus infectious diseases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
WO2003097062A1 (en) 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
JP2004043458A (en) 2002-05-22 2004-02-12 Kyorin Pharmaceut Co Ltd 4-aryl-5-hydroxyisoquinoline derivative and method for producing the same
CN1218942C (en) * 2002-06-11 2005-09-14 中南大学湘雅医学院 Antifibrosis pyridinone medicine and its prepaing process
EP1534703A2 (en) 2002-06-12 2005-06-01 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
EP1542978B1 (en) 2002-07-22 2011-04-13 Orchid Research Laboratories Limited Novel bio-active molecules
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
JP2006501215A (en) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003258305A1 (en) 2002-08-28 2004-03-19 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
JPWO2004024694A1 (en) 2002-09-10 2006-01-05 杏林製薬株式会社 4-substituted aryl-5-hydroxyisoquinolinone derivatives
JP2006506352A (en) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
CH696420A5 (en) 2002-09-13 2007-06-15 Mepha Ag New stable formulations of alkyl, phenyl-pyridones for topical use.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
EP1558606A4 (en) 2002-10-02 2008-05-07 Bristol Myers Squibb Co Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
WO2004035563A1 (en) * 2002-10-17 2004-04-29 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
PE20040844A1 (en) 2002-11-26 2004-12-30 Novartis Ag PHENYLACETIC ACIDS AND DERIVATIVES AS COX-2 INHIBITORS
JP4542743B2 (en) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 Solution pharmaceutical composition of pyridone derivatives
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20040142950A1 (en) 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (en) 2003-01-31 2005-07-13 Vertex Pharma GIRASA INHIBITORS AND USES OF THE SAME
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CL2004000234A1 (en) 2003-02-12 2005-04-15 Biogen Idec Inc DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
US20040157738A1 (en) 2003-02-12 2004-08-12 Ishihara Sangyo Kaisha, Ltd. Novel oxygen containing fused cyclic derivatives and herbicidal, desiccant and defoliate compositions containing them
PL378111A1 (en) 2003-02-14 2006-03-06 Smithkline Beecham Corporation Novel compounds
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
WO2004078174A1 (en) 2003-02-28 2004-09-16 Morgan Lee R Resonance modulator for diagnosis and therapy
EP1599171A2 (en) 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
JP2004269469A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
WO2004089914A1 (en) 2003-04-08 2004-10-21 Basf Aktiengesellschaft Benzenesulphonamide derivatives as herbicides or desiccant/defoliant compounds
JP4089491B2 (en) 2003-04-14 2008-05-28 コニカミノルタホールディングス株式会社 Polymerization initiator, polymerization composition, radical generation method, lithographic printing plate material and lithographic printing plate preparation method
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP2004359641A (en) 2003-06-06 2004-12-24 Ono Pharmaceut Co Ltd Ccr5 activator
KR20060021905A (en) 2003-06-20 2006-03-08 셀테크 알앤디 리미티드 Thienopyridone derivatives as kinase inhibitors
AU2004249498B2 (en) 2003-06-20 2009-11-19 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
JP2005013152A (en) 2003-06-27 2005-01-20 Asahi Kasei Corp Cell differentiation retarder and method for culturing cell, culture solution and cultured cell by using the same retarder
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
KR101160698B1 (en) 2003-06-27 2012-06-28 아사히 가세이 가부시키가이샤 Cell differentiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
CN1829709A (en) 2003-08-01 2006-09-06 健亚生物科技公司 Bicyclic imidazol derivatives against flaviviridae
CL2004002050A1 (en) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B COMPOUNDS DERIVED FROM REPLACED PIRIDINONES; ITS USE IN THE TREATMENT OF AFFECTIONS CAUSED OR EXACTED BY ACTIVITY P38 MAP KINASA AND / OR NON-REGULATED TNF, SUCH AS INFLAMMATIONS, TUMORS, AIDS AND OTHERS.
EP1663202A1 (en) 2003-09-04 2006-06-07 Aventis Pharmaceuticals, Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
SE0302487D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
DE10345648A1 (en) 2003-10-01 2005-04-21 Studiengesellschaft Kohle Mbh Production of new or known tetrahydropyranyl-pyridone compounds, for use as phosphatase inhibitors, e.g. for treating cancer, from pyridinone and pyranone compounds via several new intermediates
WO2005039598A1 (en) 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
JP4170198B2 (en) 2003-11-14 2008-10-22 一丸ファルコス株式会社 Cosmetic composition
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
WO2005051949A1 (en) * 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. Novel condensed imidazole derivative
DE10358004A1 (en) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam compounds and their use
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
ATE388146T1 (en) 2004-01-29 2008-03-15 Pfizer 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONIC ACID AMIDE DERIVATIVES WITH AGONISTIC EFFECT ON THE 5-HT4 RECEPTOR
GB0402812D0 (en) 2004-02-09 2004-03-10 Tanabe Seiyaku Co Novel compounds
JP2005255675A (en) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd Pharmaceutical composition
EP1742905A2 (en) 2004-02-20 2007-01-17 Japan Science and Technology Agency Process of making alfa-aminooxyketone/ alfa-aminooxyaldehyde and alfa-hydroxyketone/ alfa-hydroxyaldehyde compounds and a process of making reaction products from cyclic alfa, beta-unsaturated ketone substrates and nitroso substrates
CN1930126A (en) 2004-03-05 2007-03-14 万有制药株式会社 Pyridone derivative
PE20060285A1 (en) 2004-03-30 2006-05-08 Aventis Pharma Inc PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
JPWO2005105743A1 (en) 2004-04-28 2008-03-13 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
DE102004028973A1 (en) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituted tetrahydro-2H-isoquinolin-1-one derivatives, process for their preparation and their use as medicaments
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2006002099A2 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2006011024A2 (en) 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006020145A2 (en) 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
US7465726B2 (en) 2004-08-02 2008-12-16 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2.3-B]pyridines
US20080171755A1 (en) 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7694674B2 (en) 2004-09-21 2010-04-13 Carleton Life Support Systems, Inc. Oxygen generator with storage and conservation modes
KR101331786B1 (en) 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Inhibitors of the interaction between mdm2 and p53
US20060069260A1 (en) 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
JP4223457B2 (en) 2004-10-06 2009-02-12 本田技研工業株式会社 Electric steering device for vehicle
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2583710A1 (en) 2004-10-12 2006-04-27 Decode Genetics, Inc. Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
WO2006051826A1 (en) 2004-11-10 2006-05-18 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
WO2006055918A2 (en) 2004-11-19 2006-05-26 Pharmacopeia Drug Discovery, Inc. One-dimensional qsar models
JP2006142666A (en) 2004-11-19 2006-06-08 Mitsubishi Chemicals Corp Coloring matter for optical recording medium
AU2005309647A1 (en) 2004-11-23 2006-06-01 Wyeth Gonadotropin Releasing Hormone receptor antagonists
JP5055129B2 (en) 2004-11-24 2012-10-24 バーテックス ファーマシューティカルズ インコーポレイテッド 3- [2- (3-Acylamino-2-oxo-2H-pyridin-1-yl) -acetylamino] -4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
CA2587178A1 (en) 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
CA2588947A1 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
JPWO2006059778A1 (en) 2004-12-01 2008-06-05 萬有製薬株式会社 Substituted pyridone derivatives
CN101137651A (en) 2004-12-17 2008-03-05 安那迪斯药品股份有限公司 Pyridazinone compounds
ATE479662T1 (en) 2004-12-23 2010-09-15 Hui Yao PYRIMIDINONE COMPOUNDS, THEIR PREPARATION AND THEIR USE
CN101090889A (en) * 2004-12-29 2007-12-19 纳幕尔杜邦公司 Nepetalactams and n-substituted derivatives thereof
JP2008526769A (en) * 2004-12-29 2008-07-24 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Dihydronepetalactam and N-substituted derivatives thereof
US20060148842A1 (en) * 2004-12-29 2006-07-06 Scialdone Mark A Nepetalactams and N-substituted derivatives thereof
CN101090890A (en) * 2004-12-29 2007-12-19 纳幕尔杜邦公司 Dihydronepetalactams and n-substituted derivatives thereof
JP2008527002A (en) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders
AU2006206274A1 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20080119518A1 (en) * 2005-02-04 2008-05-22 Yuichi Suzuki 1-(Piperidin-4- Yl)-1H-Indole Derivatives
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
CN1676518B (en) 2005-03-17 2010-05-12 南开大学 4-substituted phenyl pyridazine compound and herbicidal activity
ME01224B (en) 2005-04-04 2013-06-20 Eisai R&D Man Co Ltd Dihydropyridine compounds for neurodegenerative diseases and dementia
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
CN1846699A (en) 2005-04-13 2006-10-18 中南大学湘雅医院 Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
JP5053997B2 (en) 2005-04-28 2012-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds for the treatment of inflammatory diseases
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
GB0511190D0 (en) 2005-06-01 2005-07-06 Sterix Ltd Use
AU2006255009B2 (en) 2005-06-07 2011-10-27 Pharmacopeia L.L.C. Azinone and diazinone V3 inhibitors for depression and stress disorders
WO2006133147A2 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2006131186A1 (en) 2005-06-10 2006-12-14 Merck Patent Gmbh Oxindoles as kinase inhibitors
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2006138118A2 (en) 2005-06-15 2006-12-28 New York Blood Center Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
AU2006269459B2 (en) 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007006591A2 (en) 2005-07-13 2007-01-18 Bayer Cropscience Sa Dihalogenation of n,o-disubstituted hydroxipyridones and uses thereof
JP2007063268A (en) 2005-08-05 2007-03-15 Tanabe Seiyaku Co Ltd Pharmaceutical composition
JP2007056213A (en) 2005-08-26 2007-03-08 Fujifilm Corp Composition for sintered oil-containing bearing oil, bearing device and sliding member using the same
JP5066516B2 (en) 2005-09-01 2012-11-07 アステラス製薬株式会社 Pyridazinone derivatives used for the treatment of pain
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007037543A1 (en) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Biarylamide derivative
EP1932840B1 (en) 2005-10-03 2014-04-09 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
US8372851B2 (en) 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
JP2007145819A (en) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd Pharmaceutical composition
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP1966199B1 (en) 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
AR057986A1 (en) * 2005-11-21 2008-01-09 Japan Tobacco Inc HETEROCICLICAL COMPOUND AND ITS PHARMACEUTICAL USE
JP2009517390A (en) 2005-11-23 2009-04-30 インターミューン インコーポレイテッド Methods for modulating stress-activated protein kinase systems
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
CN101304970A (en) 2005-12-21 2008-11-12 卫材R&D管理有限公司 Amorphous form of 1,2-dihydropyridine compound
US20090088574A1 (en) 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
WO2007076104A1 (en) 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2007081897A2 (en) 2006-01-11 2007-07-19 Merck & Co., Inc. Fused triazole tachykinin receptor antagonists
UY30117A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDED COMPOUND
WO2007088876A1 (en) 2006-02-02 2007-08-09 Kumiai Chemical Industry Co., Ltd. Pyridone derivative and herbicide
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
AU2007227664A1 (en) 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN100396669C (en) 2006-03-15 2008-06-25 浙江省医学科学院 Production of pyriphenanthrenone as anti-fibrosis medicine
US8088795B2 (en) 2006-03-22 2012-01-03 Janssen Pharmaceutica N.V. Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
EP2010488A2 (en) 2006-04-05 2009-01-07 Vitae Pharmaceuticals, Inc. Renin inhibitors
US20090275581A1 (en) 2006-04-05 2009-11-05 Baldwin John J Renin inhibitors
CN101460634A (en) 2006-04-13 2009-06-17 康乃尔研究基金会有限公司 Methods and compositions for targeting C-REL
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EP2013175B9 (en) 2006-05-04 2020-11-11 Macrophage Pharma Limited p38 MAP KINASE INHIBITORS
WO2007131179A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2007139150A1 (en) 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
ATE533486T1 (en) 2006-06-15 2011-12-15 Shanghai Genomics Inc USE OF PYRIDONE DERIVATIVES FOR PREVENTING AND TREATING RADIATION-RELATED LUNG INJURY
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
ES2436028T3 (en) 2006-06-23 2013-12-26 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP2046328A4 (en) 2006-07-19 2009-10-28 Univ Georgia Res Found Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
RS52626B (en) 2006-07-25 2013-06-28 Cephalon Inc. Pyridizinone derivatives
JP4747985B2 (en) 2006-08-02 2011-08-17 コニカミノルタオプト株式会社 Optical film, polarizing plate and liquid crystal display device using the same
CA2659084C (en) 2006-08-02 2011-07-12 Lg Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
NZ575520A (en) 2006-08-25 2012-03-30 Boehringer Ingelheim Int New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
CN100516126C (en) 2006-09-06 2009-07-22 北京理工大学 Ion liquid
AR063706A1 (en) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
JP2008076948A (en) 2006-09-25 2008-04-03 Konica Minolta Medical & Graphic Inc Photosensitive lithographic printing plate material
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
AU2007317296B2 (en) 2006-11-08 2012-07-05 Bristol-Myers Squibb Company Pyridinone compounds
KR20080045538A (en) 2006-11-20 2008-05-23 에스케이케미칼주식회사 A pharmaceutical compositions containing pyridine derivatives as an effective ingredient for the treatment of inflammatory disease and immune disorders
CN1962642A (en) 2006-11-21 2007-05-16 南开大学 Trifluoromethylphenylpyridazine derivative and its preparation method
GB0624105D0 (en) 2006-12-01 2007-01-10 Sterix Ltd Use
CN101541796B (en) 2006-12-05 2012-11-07 詹森药业有限公司 Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases
CA2672601A1 (en) 2006-12-14 2008-06-19 Astellas Pharma Inc. Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
EP2089397B1 (en) 2006-12-14 2012-08-29 Eli Lilly & Company 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists
JP5419706B2 (en) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド Glucokinase activator
EP2518063B1 (en) 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
EP2125778A1 (en) 2006-12-22 2009-12-02 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
WO2008077550A1 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (en) 2007-01-22 2014-07-30 Gtx公司 Nuclear receptor binding agents
CN101235030A (en) 2007-01-30 2008-08-06 中南大学 1-substituted-5-trifluoromethyl-2-(1H)pyridone compound, preparation method and use thereof
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
DE102007007751A1 (en) 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
JP5134834B2 (en) 2007-03-01 2013-01-30 東ソー株式会社 Process for producing 5,5-disubstituted-3-pyrrolin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
EP2073799A4 (en) 2007-03-12 2009-08-19 Vm Discovery Inc Novel agents of calcium ion channel modulators
PE20081882A1 (en) 2007-03-15 2008-12-27 Schering Corp USEFUL PYRIDAZINONE DERIVATIVES AS GLUCAN SYNTHASE INHIBITORS
CA2680398A1 (en) 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
CA2706017A1 (en) 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
CN101668732A (en) 2007-04-02 2010-03-10 同一世界健康研究院 CFTR inhibitor compound and uses thereof
BRPI0809998B8 (en) 2007-04-03 2021-05-25 Array Biopharma Inc imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions
US20100130471A1 (en) 2007-04-05 2010-05-27 Baldwin John J Renin Inhibitors
CL2008000973A1 (en) * 2007-04-05 2009-01-02 Astrazeneca Ab Compounds derived from 1-oxo-isoquinoline; preparation procedure; pharmaceutical composition; and its use in the treatment of chronic obstructive pulmonary diseases (COPD) and asthma.
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
MX2007006349A (en) 2007-05-29 2009-02-18 Cell Therapy And Technology S New process of synthesis for obtaining 5-methyl-1-phenyl-2 (ih) -pyridone, composition and use of the same.
WO2008147169A2 (en) 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemulsion containing pirfenidone
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
EP2170828B1 (en) 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
DE102007028406A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
EP2164489A2 (en) 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
CA2690087A1 (en) 2007-07-13 2009-01-22 Takahisa Hanada Ampa receptor antagonists and zonisamide for neuropathic pain
JP2010533127A (en) 2007-07-13 2010-10-21 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ AMPA receptor antagonists and aldose reductase inhibitors for neuropathic pain
DK2170864T3 (en) * 2007-07-17 2012-01-16 Bristol Myers Squibb Co Pyridone GPR119-G protein-coupled receptor agonists
DE102007035333A1 (en) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals
JP5436211B2 (en) 2007-08-10 2014-03-05 クミアイ化学工業株式会社 Pest control composition and pest control method
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
CN101371833A (en) 2007-08-23 2009-02-25 中南大学 Use of 1-aryl-2(1H)-pyridinone compounds in preparing medicament for curing skin pruritus
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
JP5433579B2 (en) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 1,3-disubstituted-4-phenyl-1H-pyridin-2-one
CN101652138B (en) 2007-09-19 2011-07-06 中南大学 New medicine use of 1-substituted aryl -2(1H)-pyridone
CN101121697A (en) * 2007-09-20 2008-02-13 东北师范大学 Method for synthesizing polysubstituted pyridin-2(1H)-one
WO2009054543A1 (en) 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
WO2009054544A1 (en) 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
JP5423679B2 (en) 2007-10-31 2014-02-19 日産化学工業株式会社 Pyridazinone compounds and P2X7 receptor inhibitors
WO2009060835A1 (en) 2007-11-05 2009-05-14 Kyoto University Novel ubiquilin-binding small molecule
EP2225237A2 (en) 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organic compounds
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2235161A1 (en) 2007-12-11 2010-10-06 Research Development Foundation Small molecules for neuronal differentiation of embryonic stem cells
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
WO2009082038A2 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
CN101977905B (en) 2008-01-23 2014-07-02 百时美施贵宝公司 4-pyridinone compounds and their use for cancer
JP5524082B2 (en) 2008-01-30 2014-06-18 セファロン、インク． Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands
AU2009217543A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
WO2009111785A2 (en) 2008-03-07 2009-09-11 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
US8349864B2 (en) 2008-03-25 2013-01-08 New Mexico Technical Research Foundation Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009124119A2 (en) 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2009124553A2 (en) 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
MX2010012067A (en) 2008-05-05 2010-12-06 Merck Frosst Canada Ltd 3, 4 - substituted piperidine derivatives as renin inhibitors.
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
EP2296653B1 (en) * 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2297133B1 (en) 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
US20110098324A1 (en) 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
MX2010014572A (en) 2008-06-27 2011-03-24 Novartis Ag Organic compounds.
JP5309216B2 (en) 2008-07-11 2013-10-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 4-phenoxymethylpiperidines as modulators of GPR119 activity
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
US20120040974A1 (en) 2008-08-18 2012-02-16 Yale University Mif modulators
WO2010025087A1 (en) 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CA2736970A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
WO2010048716A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
CA2746220A1 (en) 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
JP2012511514A (en) 2008-12-10 2012-05-24 メルク・カナダ・インコーポレイテツド 3,4-Substituted piperidine derivatives as renin inhibitors
KR101847887B1 (en) 2008-12-11 2018-04-11 시오노기세야쿠 가부시키가이샤 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
ES2537827T3 (en) 2009-01-07 2015-06-12 Henkel US IP LLC Hydrogen peroxide complexes and their use in an anaerobic adhesive curing system
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
JP2012516847A (en) * 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Inhibitor of AKT activity
KR101730665B1 (en) 2009-02-05 2017-04-26 다케다 야쿠힌 고교 가부시키가이샤 Pyridazinone compounds
EP2406233B1 (en) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2405913A1 (en) 2009-03-09 2012-01-18 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
JP5746135B2 (en) 2009-03-16 2015-07-08 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ Nucleic acid binding dyes and uses thereof
CN106478496A (en) 2009-03-27 2017-03-08 阿迪生物科学公司 Dihydropyridine sulfonamide and dihydropyridine sulphamide as mek inhibitor
MX2011010984A (en) 2009-04-20 2011-11-18 Marrone Bio Innovations Inc Chemical and biological agents for the control of molluscs.
CA2760151A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
JP2012131708A (en) 2009-04-28 2012-07-12 Nissan Chem Ind Ltd 4-substituted pyridazinone compound and p2x7 receptor inhibitor
WO2010129467A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
WO2010132864A1 (en) 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
KR101522924B1 (en) 2009-05-25 2015-05-26 센트럴 사우스 유니버시티 Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and salts thereof and their applications
AU2010252451B2 (en) 2009-05-25 2014-04-03 Central South University 1-(substituted benzyl)-5-trifluoromethyl-2-(1H) pyridone compounds and their salts, their preparation methods and use thereof
US20100305326A1 (en) 2009-06-02 2010-12-02 Marquette University Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage
WO2010141539A1 (en) 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2010141540A1 (en) 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
EP2437601A4 (en) 2009-06-03 2012-10-31 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
TWI434833B (en) 2009-06-03 2014-04-21 Intermune Inc Improved method for synthesizing pirfenidone
WO2010141538A1 (en) 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
WO2011077711A1 (en) 2009-12-22 2011-06-30 興和株式会社 Novel 2-pyridone derivative and pharmaceutical product containing same
BR112012025590A2 (en) * 2010-04-08 2016-06-21 Bristol Myers Squibb Co pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
PE20130376A1 (en) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
KR20120011357A (en) * 2010-07-23 2012-02-08 현대약품 주식회사 Substituted pyridinone derivatives and methods for manufacturing the same
CN103140221A (en) * 2010-08-10 2013-06-05 盐野义制药株式会社 Novel heterocyclic derivatives and pharmaceutical composition containing same
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
CN102432598A (en) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
US8643700B2 (en) * 2010-11-17 2014-02-04 Dell Products L.P. 3D content adjustment system
JP2013544854A (en) 2010-12-06 2013-12-19 グラクソ グループ リミテッド Compound
CN102558147B (en) * 2010-12-23 2014-09-17 江苏先声药物研究有限公司 Compound, and preparation method and application thereof
KR101928505B1 (en) 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 Pharmaceutical composition comprising pyridone derivatives
KR101925971B1 (en) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 Pharmaceutical composition comprising pyridone derivatives
ES2913095T3 (en) 2011-01-31 2022-05-31 Avalyn Pharma Inc Aerosolized pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012107831A1 (en) 2011-02-11 2012-08-16 Signa S.A. De C.V. Method of making a pyridone compound, 5-ethyl-1-phenyl-2-(1h)-pyridone, and intermediates thereof
FI20115234A0 (en) * 2011-03-08 2011-03-08 Biotie Therapies Corp New pyridazinone and pyridone compounds
AU2012225611B2 (en) 2011-03-08 2016-09-15 Auspex Pharmaceuticals, Inc. Substituted N-Aryl pyridinones
WO2012162592A1 (en) 2011-05-25 2012-11-29 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
CN103582728A (en) * 2011-05-27 2014-02-12 简森丹麦有限公司 A method and a feeder for feeding pieces of cloth
CN102816175B (en) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 A kind of heterocycle pyridine compounds, its intermediate, preparation method and purposes
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
WO2013004652A1 (en) * 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
WO2013018685A1 (en) 2011-07-29 2013-02-07 東レ株式会社 Lactam derivative and use thereof for medical purposes
CN102276616B (en) * 2011-08-04 2013-09-04 中国科学院长春应用化学研究所 Method for synthesizing furan[3,2-c] pyridine-4(5H) ketone compound
AU2012297569B2 (en) 2011-08-16 2017-11-09 Baker Heart and Diabetes Institute Controlled-release formulation
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
EP2785695B1 (en) * 2011-11-30 2020-06-17 F.Hoffmann-La Roche Ag New bicyclic dihydroisoquinoline-1-one derivatives
UA116774C2 (en) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Serine/threonine kinase inhibitors
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014012360A1 (en) 2012-07-18 2014-01-23 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
AU2013295800A1 (en) 2012-07-24 2015-03-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds
US20140094456A1 (en) 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
UA111305C2 (en) * 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
JP6256187B2 (en) 2014-05-14 2018-01-10 株式会社デンソー Decision feedback equalizer

Also Published As

Publication number Publication date
US9359379B2 (en) 2016-06-07
ES2835331T3 (en) 2021-06-22
HK1212981A1 (en) 2016-06-24
IL270414B (en) 2021-09-30
PE20151415A1 (en) 2015-10-16
US20180064692A1 (en) 2018-03-08
US20190321343A1 (en) 2019-10-24
US20150266899A1 (en) 2015-09-24
AU2013327505A1 (en) 2015-04-30
ECSP15017109A (en) 2016-01-29
NZ745814A (en) 2019-05-31
KR102176667B1 (en) 2020-11-10
PH12015500735B1 (en) 2015-06-01
TW201925174A (en) 2019-07-01
CN108503575A (en) 2018-09-07
US9675593B2 (en) 2017-06-13
KR102277608B1 (en) 2021-07-15
JP2018135356A (en) 2018-08-30
US10376497B2 (en) 2019-08-13
HUE051581T2 (en) 2021-03-01
EA034171B1 (en) 2020-01-14
CL2015000816A1 (en) 2015-08-28
AR092742A1 (en) 2015-04-29
SI2903991T1 (en) 2021-01-29
JP6744355B2 (en) 2020-08-19
AU2013327505B2 (en) 2018-04-19
MX2015003918A (en) 2015-08-05
PL2903991T3 (en) 2021-03-08
PH12015500735A1 (en) 2015-06-01
EA201590477A1 (en) 2015-09-30
CA3147961A1 (en) 2014-04-10
AU2018204894B2 (en) 2020-05-21
LT2903991T (en) 2020-12-28
EA201790137A1 (en) 2017-11-30
PT2903991T (en) 2020-12-15
TW201414716A (en) 2014-04-16
CA2884251A1 (en) 2014-04-10
EP2903991A4 (en) 2016-09-07
US20140107110A1 (en) 2014-04-17
ZA201502457B (en) 2021-09-29
IL277341A (en) 2020-10-29
BR112015006341B1 (en) 2022-05-31
CN104822687A (en) 2015-08-05
CN104822687B (en) 2018-11-02
JP6326053B2 (en) 2018-05-16
PE20211501A1 (en) 2021-08-11
US10898474B2 (en) 2021-01-26
BR112015006341A2 (en) 2017-07-04
CR20150225A (en) 2015-06-11
NZ707083A (en) 2018-08-31
MX2020010037A (en) 2022-05-26
TWI734049B (en) 2021-07-21
TWI644898B (en) 2018-12-21
KR20150064746A (en) 2015-06-11
IL237629A0 (en) 2015-04-30
UA120908C2 (en) 2020-03-10
US20160263090A1 (en) 2016-09-15
EA027120B1 (en) 2017-06-30
WO2014055548A1 (en) 2014-04-10
EP2903991A1 (en) 2015-08-12
IL237629B (en) 2020-09-30
MY174897A (en) 2020-05-20
DK2903991T3 (en) 2020-10-19
HRP20201934T1 (en) 2021-04-16
SA515360217B1 (en) 2017-06-18
KR20200130480A (en) 2020-11-18
JP2016500661A (en) 2016-01-14
CO7350637A2 (en) 2015-08-10
IL277341B2 (en) 2023-06-01
CA2884251C (en) 2022-07-05
AU2018204894A1 (en) 2018-07-26
RS61225B1 (en) 2021-01-29
EP2903991B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
IL277341A (en) Anti-fibrotic pyridinones
IL254716A0 (en) Zinc-lysine complex
HK1203504A1 (en) Pyridone derivative
IL237163A (en) Bicyclic pyridinones
GB2506525B (en) Lockbolt
EP2910004A4 (en) Limiting movement
GB2501004B (en) Two piece drysuit
GB2500464B (en) Toaster
HK1215569A1 (en) Pyridone compound
AU4710P (en) Fusion xTriticosecale
AU346942S (en) Jeans
AU343433S (en) Jeans
GB201219337D0 (en) Garrods movement
PL2677099T3 (en) Safety cabinet
AU345988S (en) Toaster
AU343931S (en) Pants
AU343434S (en) Pants
AU343435S (en) Pants
GB201218269D0 (en) Improved garment
GB201206799D0 (en) Improved garment